Free Trial
NASDAQ:PDSB

PDS Biotechnology (PDSB) Stock Price, News & Analysis

PDS Biotechnology logo
$0.96 -0.06 (-5.62%)
Closing price 04:00 PM Eastern
Extended Trading
$0.97 +0.00 (+0.34%)
As of 05:27 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About PDS Biotechnology Stock (NASDAQ:PDSB)

Advanced

Key Stats

Today's Range
$0.96
$1.04
50-Day Range
$1.01
$1.30
52-Week Range
$0.85
$3.79
Volume
886,811 shs
Average Volume
544,316 shs
Market Capitalization
$45.28 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$10.00
Consensus Rating
Hold

Company Overview

PDS Biotechnology Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
34th Percentile Overall Score

PDSB MarketRank™: 

PDS Biotechnology scored higher than 34% of companies evaluated by MarketBeat, and ranked 746th out of 937 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    PDS Biotechnology has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 2 buy ratings, no hold ratings, and 1 sell rating.

  • Upside Potential

    PDS Biotechnology has a consensus price target of $10.00, representing about 908.1% upside from its current price of $0.99.

  • Amount of Analyst Coverage

    PDS Biotechnology has only been the subject of 1 research reports in the past 90 days.

  • Read more about PDS Biotechnology's stock forecast and price target.
  • Earnings Growth

    Earnings for PDS Biotechnology are expected to decrease in the coming year, from ($1.20) to ($1.35) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of PDS Biotechnology is -1.08, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of PDS Biotechnology is -1.08, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    PDS Biotechnology has a P/B Ratio of 1.95. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about PDS Biotechnology's valuation and earnings.
  • Percentage of Shares Shorted

    3.72% of the outstanding shares of PDS Biotechnology have been sold short.
  • Short Interest Ratio / Days to Cover

    PDS Biotechnology has a short interest ratio ("days to cover") of 3.5, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in PDS Biotechnology has recently decreased by 5.41%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    PDS Biotechnology does not currently pay a dividend.

  • Dividend Growth

    PDS Biotechnology does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    3.72% of the outstanding shares of PDS Biotechnology have been sold short.
  • Short Interest Ratio / Days to Cover

    PDS Biotechnology has a short interest ratio ("days to cover") of 3.5, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in PDS Biotechnology has recently decreased by 5.41%, indicating that investor sentiment is improving significantly.
  • Search Interest

    10 people have searched for PDSB on MarketBeat in the last 30 days. This is an increase of 150% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, PDS Biotechnology insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 9.20% of the stock of PDS Biotechnology is held by insiders.

  • Percentage Held by Institutions

    Only 26.84% of the stock of PDS Biotechnology is held by institutions.

  • Read more about PDS Biotechnology's insider trading history.
Receive PDSB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for PDS Biotechnology and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

PDSB Stock News Headlines

An $8 trillion-dollar discovery 17,000 ft underwater
A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materials critical for AI chips, EV batteries, smartphones, and advanced weapons systems. While few people know about these metals, global powers—including the U.S., China, and Russia—are racing to secure them. And one tiny public company, recently backed by the U.S. government, holds mining rights to over 340 million tons… and near-monopoly access to the richest zone.tc pixel
See More Headlines

PDSB Stock Analysis - Frequently Asked Questions

PDS Biotechnology's stock was trading at $1.63 on January 1st, 2025. Since then, PDSB shares have decreased by 39.1% and is now trading at $0.9920.

PDS Biotechnology Corporation (NASDAQ:PDSB) announced its quarterly earnings results on Wednesday, August, 13th. The company reported ($0.21) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.24) by $0.03.
Read the conference call transcript
.

Shares of PDSB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that PDS Biotechnology investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), CymaBay Therapeutics (CBAY), Adobe (ADBE), Broadcom (AVGO) and CrowdStrike (CRWD).

Company Calendar

Last Earnings
8/13/2025
Today
10/06/2025
Next Earnings (Estimated)
11/13/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:PDSB
CIK
1472091
Employees
20
Year Founded
2005

Price Target and Rating

High Price Target
$13.00
Low Price Target
$7.00
Potential Upside/Downside
+880.4%
Consensus Rating
Hold
Rating Score (0-4)
2.33
Research Coverage
3 Analysts

Profitability

EPS (Trailing Twelve Months)
($0.92)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$37.61 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-184.56%
Return on Assets
-79.00%

Debt

Debt-to-Equity Ratio
0.81
Current Ratio
2.92
Quick Ratio
2.92

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.51 per share
Price / Book
2.00

Miscellaneous

Outstanding Shares
47,030,000
Free Float
42,700,000
Market Cap
$47.97 million
Optionable
Optionable
Beta
1.11

Social Links

7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

This page (NASDAQ:PDSB) was last updated on 10/6/2025 by MarketBeat.com Staff
From Our Partners